House E&C Subcommittee on Health Holds Another Hearing on Health Care Affordability
The House Committee on Energy and Commerce Subcommittee on Health held another hearing on June 10 in its affordability series to explore more...
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3

The House Committee on Energy and Commerce Subcommittee on Health held another hearing on June 10 in its affordability series to explore more...
Lincoln, NE - June 16, 2026 TELCOR QML® has connectivity for more than 160 device types. Whether you are looking to add new testing on devices...
Lincoln, NE – June 12, 2026 – TELCOR Inc, the industry leader in healthcare software for point of care testing and laboratory revenue cycle...